175 related articles for article (PubMed ID: 36786135)
1. Cardiac Injury Following Chemo/Radiation Therapy: An Updated Review on Mechanisms and Therapeutic Approaches.
Singh K; A Alameri A; Ali Hamza A; E Al-Gazally M; Temurovich Islomov S; Fadhel Obaid R; Alexis Ramírez-Coronel A; Abosaooda M; Yahyapour R; Najafi M
Curr Radiopharm; 2023 Jun; 16(3):185-203. PubMed ID: 36786135
[TBL] [Abstract][Full Text] [Related]
2. Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents.
Yang R; Tan C; Najafi M
Inflammopharmacology; 2022 Feb; 30(1):73-89. PubMed ID: 34813027
[TBL] [Abstract][Full Text] [Related]
3. Redox interactions-induced cardiac toxicity in cancer therapy.
Fu X; Tang J; Wen P; Huang Z; Najafi M
Arch Biochem Biophys; 2021 Sep; 708():108952. PubMed ID: 34097901
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications.
Zhao W; Robbins ME
Curr Med Chem; 2009; 16(2):130-43. PubMed ID: 19149566
[TBL] [Abstract][Full Text] [Related]
5. Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M; Li Y; Li S; Lv J
Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
[TBL] [Abstract][Full Text] [Related]
6. Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics.
Yahyapour R; Motevaseli E; Rezaeyan A; Abdollahi H; Farhood B; Cheki M; Rezapoor S; Shabeeb D; Musa AE; Najafi M; Villa V
Clin Transl Oncol; 2018 Aug; 20(8):975-988. PubMed ID: 29318449
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Remodelling Following Cancer Therapy: A Review.
Panpan T; Yuchen D; Xianyong S; Meng L; Ruijuan H; Ranran D; Pengyan Z; Mingxi L; Rongrong X
Cardiovasc Toxicol; 2022 Sep; 22(9):771-786. PubMed ID: 35877038
[TBL] [Abstract][Full Text] [Related]
8. NADPH Oxidase as a Target for Modulation of Radiation Response; Implications to Carcinogenesis and Radiotherapy.
Mortezaee K; Goradel NH; Amini P; Shabeeb D; Musa AE; Najafi M; Farhood B
Curr Mol Pharmacol; 2019; 12(1):50-60. PubMed ID: 30318012
[TBL] [Abstract][Full Text] [Related]
9. The Role of Mitochondrial Dysfunction in Radiation-Induced Heart Disease: From Bench to Bedside.
Livingston K; Schlaak RA; Puckett LL; Bergom C
Front Cardiovasc Med; 2020; 7():20. PubMed ID: 32154269
[TBL] [Abstract][Full Text] [Related]
10. Redox Interactions in Chemo/Radiation Therapy-induced Lung Toxicity; Mechanisms and Therapy Perspectives.
Lai X; Najafi M
Curr Drug Targets; 2022; 23(13):1261-1276. PubMed ID: 35792117
[TBL] [Abstract][Full Text] [Related]
11. Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage.
Choi KJ; Nam JK; Kim JH; Choi SH; Lee YJ
Exp Mol Med; 2020 May; 52(5):781-792. PubMed ID: 32467609
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cellular redox metabolism for mitigation of radiation injury.
Farhood B; Ashrafizadeh M; Khodamoradi E; Hoseini-Ghahfarokhi M; Afrashi S; Musa AE; Najafi M
Life Sci; 2020 Jun; 250():117570. PubMed ID: 32205088
[TBL] [Abstract][Full Text] [Related]
13. New Insights into the Understanding of Mechanisms of Radiation-Induced Heart Disease.
Wang KX; Ye C; Yang X; Ma P; Yan C; Luo L
Curr Treat Options Oncol; 2023 Jan; 24(1):12-29. PubMed ID: 36598620
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
15. Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials.
Liao Y; Meng Q
Environ Res; 2023 Dec; 238(Pt 2):116896. PubMed ID: 37586453
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced kidney toxicity: molecular and cellular pathogenesis.
Klaus R; Niyazi M; Lange-Sperandio B
Radiat Oncol; 2021 Feb; 16(1):43. PubMed ID: 33632272
[TBL] [Abstract][Full Text] [Related]
17. Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation.
You S; Qian J; Wu G; Qian Y; Wang Z; Chen T; Wang J; Huang W; Liang G
Phytomedicine; 2019 Sep; 62():152955. PubMed ID: 31146168
[TBL] [Abstract][Full Text] [Related]
18. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.
Maisch B; Hufnagel G; Kölsch S; Funck R; Richter A; Rupp H; Herzum M; Pankuweit S
Herz; 2004 Sep; 29(6):624-36. PubMed ID: 15912438
[TBL] [Abstract][Full Text] [Related]
19. Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway.
Li X; Sun S; Chen D; Yuan T; Chen Y; Wang D; Fang L; Lu Y; Du G
Eur J Pharmacol; 2020 Nov; 886():173472. PubMed ID: 32860809
[TBL] [Abstract][Full Text] [Related]
20. Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms.
Xu C; Shang Z; Najafi M
Curr Drug Targets; 2022; 23(16):1505-1525. PubMed ID: 36082868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
